Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Topography-guided photorefractive keratectomy with simultaneous cross-linking in patients with early and moderate keratoconus

Poster Details

First Author: F.Abdulaliyeva AZERBAIJAN

Co Author(s):    T. Huseynova                    

Abstract Details

Purpose:

To evaluate the clinical outcomes after simultaneous topography-guided photorefractive keratectomy (PRK) and crosslinking (CXL) in patients with early and moderate keratoconus.

Setting:

National Ophthalmology Center named after Z.Aliyeva, Baku, Azerbaijan.

Methods:

Twenty patients (30 eyes) with early and moderate keratoconus were included in the study. All patients underwent customized topography-guided PRK which was immediately followed by the CXL procedure. The epithelium was removed by transepithelial phototherapeutic keratectomy in all cases. Uncorrected distance visual acuity (UDVA), manifest refraction spherical equivalent (MRSE), endothelial cell density (ECD), and also parameters from Pentacam topography (Oculus, Wetzlar, Germany) were evaluated pre- and postoperatively. The follow up period was 24 months.

Results:

There was a significant difference in UDVA, MRSE, and keratometry values (p<0.05 for all) postoperatively. The parameters of corneal variance indices, such as Index of Surface Variance (ISV), Index of Vertical Asymmetry (IVA), Center keratoconus Index (CKI), Index of Height Asymmetry (IHA) and Index of Height Decentration (IHD), radius minimum (RM) from Pentacam, were also changed significantly (p<0.05 for all).

Conclusions:

Simultaneous PRK and CXL are considered as an alternative treatment in our series of early and moderate keratoconic patients.

Financial Disclosure:

NONE

Back to Poster listing